title: Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.
abstract: Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life. Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab. Immunological analyses showed an initial increase in proportion and function of CD8(+) effector T cells and a reduction of circulating T(reg) cells. A review of the current literature regarding bevacizumab in ovarian cancer is reported. Bevacizumab has shown a high efficacy in the treatment of ovarian cancer. Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.
authors: Institute of Gynecology and Obstetrics, Sapienza University, Rome, Italy. filippo.bellati@uniroma1.it
authors: Filippo
authors: F
authors: Bellati
authors: Chiara
authors: C
authors: Napoletano
authors: Ilary
authors: I
authors: Ruscito
authors: Maria
authors: M
authors: Pastore
authors: Milena
authors: M
authors: Pernice
authors: Morena
authors: M
authors: Antonilli
authors: Marianna
authors: M
authors: Nuti
authors: Pierluigi
authors: P
authors: Benedetti Panici
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001201:Ascites / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D000068258:Bevacizumab; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000096:biosynthesis; D016131:Lymphocyte Subsets / Q000276:immunology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications* / Q000276:immunology; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D007371:Interferon-gamma